• Explore /
  • Videos & Slides
  • / A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, <em>ex vivo</em>-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.

A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.

Abstract Video & Slides Poster

Presenter

null

Michael Heuser, MD

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

EudraCT number 2019-003686-17

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS7053)

DOI

10.1200/JCO.2021.39.15_suppl.TPS7053

Abstract #

TPS7053

Poster Bd #

Online Only

Abstract Disclosures

Similar Videos & Slides

Speaker: Lei Wang, MD

Speaker: Elizabeth Fox, MD

Videos & Slides

2024 ASCO Annual Meeting

Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.

Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.

Speaker: Daniel Alexander Morgenstern, PhD, MBBChir

Speaker: Lin Shen, MD